Denver, February 12, 2026 — Imagine a future where doctors know *days* in advance if a trauma patient is likely to develop life-threatening complications. Researchers at the University of Colorado Anschutz Medical Campus are making that future a reality, using a novel approach to predict recovery trajectories by analyzing molecules in the blood.
Decoding the Body’s Response to Injury
A new study reveals that “omics” markers can predict trauma outcomes with up to 92% accuracy.
- Researchers mapped molecular “endotypes” – unique biological profiles – in over 1,300 trauma patients.
- Omics markers, biological signals in blood, proved more accurate than traditional injury assessments.
- The findings pave the way for personalized trauma care tailored to individual patient responses.
- The team is developing rapid, point-of-care testing for emergency and military settings.
It’s a frustrating reality for emergency room physicians: two patients can arrive with seemingly identical injuries, yet one recovers smoothly while the other spirals into organ failure. Why? A team led by Mitchell Cohen, professor of surgery at CU Anschutz, believes the answer lies in understanding each patient’s unique biological response to trauma. “Two patients often arrive in the ER with nearly identical injuries but go on to have widely divergent outcomes despite similar care,” Cohen explained. “This occurs because their biologic response to injury and treatment is different, and our novel approach and modeling allow us to see those differences in real time, which could fundamentally change our practice.”
Beyond Traditional Measures
The study, published today in Science Translational Medicine, demonstrates that analyzing “omics” markers – a combination of proteomics (proteins) and metabolomics (metabolites) – provides a far more nuanced picture than relying solely on traditional injury severity scores. Researchers tracked over 1,300 trauma patients over time, identifying patterns that accurately predicted organ failure and mortality.
A: Yes. This research shows that analyzing molecules in the blood—specifically proteins and metabolites—can predict which patients are at risk of complications like organ failure with up to 92% accuracy, allowing for earlier and more targeted interventions.
These initial findings were further validated in an independent group of over 300 trauma patients, confirming the predictive power of the omics-based approach. According to Kirk Hansen, professor of biochemistry at CU Anschutz and co-senior author, “This is precision medicine for trauma. By combining proteomics and metabolomics data, we can not only predict outcomes more accurately than traditional methods, but also start to understand the biology that drives those outcomes.”
The Future of Personalized Trauma Care
The implications extend beyond prediction. The researchers are actively working to adapt their molecular profiling approach into a rapid, point-of-care test suitable for use in emergency departments and even on the battlefield. “Our colleagues at CU Anschutz are also about to embark on the first ever U.S. trial of a fibrinogen supplementation for trauma care in injuries on and off the battlefield. This work will directly affect how we think about the planning, conduct and results of that trial,” Cohen added, highlighting the collaborative spirit driving trauma research at the campus.
Angelo D’Alessandro, co-senior author and professor of biochemistry at CU Anschutz, emphasized the broader potential of this work. “This is precision metabolic health in action, validated in an independent cohort and ready for clinical use today,” he said. “The same science that can forecast a trauma patient’s outcome days in advance also powers tools to understand how the body responds to extreme endurance and to safeguard the quality of donated blood.”
The study was co-authored by Jessica Cardenas, Christopher Silliman, Anirban Banerjee, and Christopher Erickson, and was funded by the National Institutes of Health and the Department of Defense.
“The future of personalized health isn’t decades away – it’s here now, for those with the vision to put it into practice.”
